12 December 2012


(“Sareum” or “the Company”)

Annual General Meeting Statement

Sareum, the specialist cancer drug discovery business, will be holding its Annual General Meeting (“AGM”) at 10:00am today, 12 December 2012, at the offices of Merchant Securities Limited, 51-55 Gresham Street, London EC2V 7EL.

During the AGM, Dr. Paul Harper, the Company’s Chairman, will be making the following statement:

“Sareum has made good progress during the year in a number of key areas and we continue to focus on commercialising our research programmes to fund the future growth of the Company.

Although collaboration and licensing discussions around a number of programmes continue, it has become increasingly apparent that the opportunity of concluding such a deal before the calendar year-end is now less likely than the Board had previously anticipated. However, the Board remains confident that a commercial deal with one or more of its programmes will be concluded.

We remain focused on maximising the opportunities for commercial exploitation however they arise. The addition of the £4 million SEDA financing facility, from which the first tranche of funding was drawn down last week, gives us considerable flexibility in funding further development work, as well as putting us in a strong position to negotiate with collaborators and possible partners.”


For further information:


Sareum Holdings plc


Tim Mitchell

01223 497 700

Merchant Securities Limited (Nomad)

Simon Clements

020 7628 2200

Hybridan LLP (Broker)


Claire Noyce, Deepak Reddy

020 7947 4350

Media enquiries:


The Communications Portfolio Ltd


Philip Ranger / Caolan Mahon

020 7536 2028/2029



Notes for editors:

About Sareum Holdings plc

Sareum is a drug discovery company, headquartered in Cambridge UK, that produces targeted small molecule therapeutics, focusing on cancer and auto-immune disease. Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum’s Chk1 kinase cancer research programme is a joint research collaboration with The Institute of Cancer Research and Cancer Research Technology Limited. The development candidate resulting from the collaboration increases the effectiveness of current cancer therapeutics in several in-vivo cancer models.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum’s drug discovery technology platform that has so far produced the Company’s Aurora+FLT3, Aurora+ALK VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange and trades under the symbol SAR.  For further information, please visit www.sareum.co.uk